Last reviewed 2026-04-22 · How we verify

Bevacizumab (Lumiere®)

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Metastatic breast cancer.

At a glance

Mechanism of action

Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and growth, often used in combination with chemotherapy or other targeted agents.

Approved indications

• Metastatic colorectal cancer
• Non-small cell lung cancer
• Metastatic breast cancer
• Renal cell carcinoma
• Glioblastoma

Common side effects

• Hypertension
• Proteinuria
• Bleeding/hemorrhage
• Thromboembolic events
• Gastrointestinal perforation
• Wound healing complications
• Fatigue

Key clinical trials

• Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bevacizumab (Lumiere®) CI brief — competitive landscape report
• Bevacizumab (Lumiere®) updates RSS · CI watch RSS
• Laboratorio Elea Phoenix S.A. portfolio CI